Supartz vs. Synvisc – Comparing Viscosupplementation Treatments

Osteoarthritis, a common joint disease affecting the aging population, results from gradual cartilage breakdown. As cartilage wears out, bones come into contact, causing pain, inflammation, and stiffness. Viscosupplementation treatments aim to alleviate symptoms. 

Supartz and Synvisc are hyaluronic acid-based injections that restore joint lubrication, protect against further damage, and reduce adverse effects. While both medications are similar, there are key differences. 

In this article, we’ll delve into the nuances of Supartz and Synvisc, comparing their efficacy, chemical formulations, and administration protocols. 

Key Takeaways

• Supartz and Synvisc are both viscosupplementation treatments used for knee osteoarthritis.
• Supartz is purified sodium hyaluronate, while Synvisc is a hylan G-F 20 gel.
• The mechanisms of action for Supartz and Synvisc involve restoring the lubricating and cushioning properties of the synovial fluid in the knee joint.
• Clinical trials have shown that both Supartz and Synvisc effectively reduce pain and improve knee function in patients with osteoarthritis.
• The safety profiles of Supartz and Synvisc are generally favorable, with mild and transient side effects.
• Dosing schedules and administration techniques differ between the two treatments, and patient preferences play a role in treatment selection.

About: DoctorMedica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to buy Supartz wholesale for your practice, the sales representatives at Doctor Medica can give you guidance.

Introduction to Viscosupplementation

Viscosupplementation is a medical process that involves injecting hyaluronic acid (HA) into the knee joint to ease pain and improve movement for those with knee osteoarthritis. This treatment mimics the natural protective functions of hyaluronan in joints, enhancing joint lubrication and restoring normal synovial fluid viscosity.

The goal is to combat osteoarthritis progression strategically. Studies have shown that such treatments can delay total knee replacement surgeries by over seven years for 75% of patients treated with Hylan G-F 20 injections. By regulating inflammatory cytokines, these injections address the root causes of pain and stiffness, offering significant relief and improved quality of life.

Composition and Mechanism of Action

Supartz is made from a fluid called hyaluronic acid (HA). This fluid is very similar to the natural substance in our knee joints that helps them move smoothly. With osteoarthritis, the HA in the knees breaks down, which can cause pain because the bones start rubbing together without enough cushioning.

Synvisc, on the other hand, is a game-changer in the fight against knee osteoarthritis. It’s made from hyaluronic acid (HA), similar to the substance naturally found in our joints. This unique formulation aims to mimic healthy, young synovial fluid—the stuff that keeps our knees moving smoothly.

Aspect	Supartz	Synvisc
Composition	Highly purified, high molecular weight sodium hyaluronate. Contains 10mg sodium hyaluronate per 1mL.	Highly cross-linked, avian-sourced hyaluronan. Contains formaldehyde and divinyl sulfone.
Mechanism of Action	Improves knee joint function by reducing joint sounds and enhancing the range of motion through its viscoelastic properties.	It mimics the properties of healthy young adult synovial fluid to cushion and lubricate the knee joint, potentially leading to local/immunological reactions due to its composition.
Safety Concerns	Linked with fewer acute inflammatory reactions.	Associated with severe acute inflammatory reactions, likely due to components like formaldehyde and divinyl sulfone.
Disease-specific Costs	Lower compared to Synvisc and Orthovisc.	Higher disease-specific costs (9.0%, p<0.0001 and 6.8%, p=0.0050 compared to Supartz/Hyalgan).

Clinical Efficacy

Supartz has been studied in many clinical trials to see how well it works for knee osteoarthritis. These studies examined whether Supartz can reduce knee pain and improve joint function. They found that many people who got Supartz felt better and could move more quickly.

As for Synvisc, further research supports its effectiveness in managing knee pain and improving joint function. A pilot study on its safety and efficacy revealed positive outcomes among patients with symptomatic tibiofemoral osteoarthritis.

Patients reported noticeable improvements in knee function and reduced pain levels, highlighting Synvisc’s role as a valuable option in osteoarthritis management strategies.

Safety Profiles

Since its FDA approval, Supartz has been a reliable option for doctors treating knee osteoarthritis. Studies from the Hospital for Special Surgery in New York and the University of South Carolina School of Medicine show that Supartz injections are safe for patients.

Compared to corticosteroid injections, Supartz offers symptomatic relief with fewer risks. Most patients experience minimal Supartz side effects, making it a desirable choice among FDA-approved viscosupplementation products.

Similarly, Synvisc is known for its positive outcomes, reducing joint pain and improving function in people with knee osteoarthritis. Made of a substance similar to hyaluronic acid, Synvisc cushions and lubricates the joint, providing longer relief than corticosteroid injections.

Practical Considerations and Patient Preferences

Supartz helps people with knee osteoarthritis. It is given through injections into the knee.

• Supartz is given in 3-5 weekly injections.
• Each injection contains 2.5 ml of the solution.
• There is no option for a generic version of Supartz.
• Information on pricing and coupons for Supartz cannot be found easily.
• Patients have rated Supartz with an average score of 6.2 out of 10.
• About 49% of users reported feeling better after using it.
• However, 36% did not find relief with this treatment.
• Supartz is recognized as a viscosupplementation agent in medical circles.

Synvisc is known for its specific dosing schedule, which sets it apart from other treatments and makes it a pivotal choice in managing knee osteoarthritis.

• Synvisc, or Hylan G-F 20, is given as three injections.
• Each injection is spaced one week apart, providing flexibility and efficiency in treatment planning.
• This regimen allows targeted pain relief over time, aligning with patient needs.
• The comparison study highlights Hylan G-F 20’s superiority in pain relief and cost-effectiveness for early osteoarthritic knees.
• For patients with symptomatic tibiofemoral osteoarthritis, this dosing schedule offers a promising treatment pathway.
• Ultimately, carefully selecting dosing schedules such as Synvisc’s contributes significantly to effective pain management strategies in knee osteoarthritis cases.

Patient Preferences and Considerations for Choosing Between Supartz and Synvisc

Choosing between Supartz and Synvisc depends on patient preferences. Synvisc-One requires only a single injection compared to Supartz’s 3-5 weekly injections, making it convenient for those who prefer fewer doctor visits.

Studies suggest that Supartz may delay the need for total knee replacement longer than Synvisc. Hazard ratios indicate a higher risk of knee replacement surgery for Synvisc patients than Supartz.

Cost is another factor, with Supartz often being more cost-effective. Research shows that Supartz/Hyalgan treatments have lower disease-specific costs than Synvisc. Safety is also essential; repeat injections of Supartz have been deemed safe, appealing to those seeking long-term management of knee osteoarthritis.

Considering these factors—number of injections, potential delays in surgery, safety profiles, and cost differences—patient preferences will vary based on individual priorities and circumstances.

Conclusion

Deciding between Supartz and Synvisc offers options for those with knee osteoarthritis. Both bring pain relief similarly but differ in composition and how often they’re given.

Knowing their safety, how well they work, and what patients prefer helps make a choice. It comes down to personal needs and a doctor’s advice. This comparison sheds light on two critical players in viscosupplementation treatments, guiding informed decisions.

FAQs

1. What’s the difference between Supartz and Synvisc?

Supartz is often given in a series of injections, while Synvisc can be just one shot.

2. How long do these treatments last?

Both treatments aim to relieve pain for about six months, but it depends on the person.

3. Are there any side effects?

Yes, both can have side effects like pain or swelling at the injection site.

4. Can anyone get these treatments?

Only some people, like your doctor, will decide if you’re a good fit based on your knee issues.

5. Do I need to rest after getting Supartz or Synvisc injections?

Rest is usually recommended, but you should follow your doctor’s advice on what’s best for you.

References

Johns Hopkins Medicine. (n.d.). Viscosupplementation treatment for arthritis. Johns Hopkins Medicine. Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/arthritis/viscosupplementation-treatment-for-arthritis

Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R., & Wells, G. (2006). Viscosupplementation for the treatment of osteoarthritis of the knee. The Cochrane database of systematic reviews, 2006(2), CD005321. https://doi.org/10.1002/14651858.CD005321.pub2

Bronstone, A., Neary, J. T., Lambert, T. H., & Dasa, V. (2019). Supartz (Sodium Hyaluronate) for the Treatment of Knee Osteoarthritis: A Review of Efficacy and Safety. Clinical medicine insights. Arthritis and musculoskeletal disorders, 12, 1179544119835221. https://doi.org/10.1177/1179544119835221